Valuation: ORIC Pharmaceuticals, Inc.

Market Cap 1.13B 991M 914M 845M 1.6B 108B 1.63B 10.94B 4.29B 53.08B 4.25B 4.16B 184B P/E 2026 *
-7.51x
P/E 2027 * -6.8x
Enterprise Value 1.02B 895M 825M 764M 1.45B 97.66B 1.47B 9.88B 3.87B 47.96B 3.84B 3.76B 166B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.15%
Yield 2026 *
-
Yield 2027 * -
1 week-5.68%
Current month+1.19%
1 month+40.19%
3 months+8.02%
6 months+21.48%
Current year+38.20%
1 week 9.04
Extreme 9.044
10.25
1 month 6.45
Extreme 6.446
10.25
3 years 3.7
Extreme 3.7
14.9
5 years 2.2
Extreme 2.2
21.2
Manager TitleAgeSince
Chief Executive Officer 47 06/05/2018
Director of Finance/CFO 52 31/08/2019
Chief Tech/Sci/R&D Officer - 17/08/2025
Director TitleAgeSince
Chairman 68 06/03/2018
Director/Board Member 47 06/05/2018
Director/Board Member 62 31/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
-1.06%-5.68%+0.91%+37.21% 1.13B
-0.33%-4.38%+63.66%+125.94% 56.98B
+4.91%-0.19%+73.70%+92.14% 53.58B
+1.48%+5.97%+22.59%+495.47% 25.63B
-0.59%-4.68%-16.82%-12.99% 23.51B
+2.43%+1.06%+47.70%-0.11% 19.43B
-0.97%+2.33%+37.11%-25.17% 18.12B
-6.84%+2.18%+203.03%+348.11% 16.46B
+8.74%+3.51%+53.81% - 14.13B
+1.76%+2.24%+29.57%+195.70% 14.35B
Average +1.18%+0.86%+51.53%+139.59% 26.91B
Weighted average by Cap. +1.39%-0.31%+57.07%+142.36%

Financials

2026 *2027 *
Net sales - -
Net income -156M -137M -126M -117M -221M -14.92B -225M -1.51B -592M -7.32B -587M -574M -25.37B -190M -166M -153M -142M -269M -18.1B -273M -1.83B -718M -8.89B -712M -697M -30.79B
Net Debt -109M -95.64M -88.19M -81.6M -155M -10.44B -157M -1.06B -414M -5.12B -410M -402M -17.75B -231M -202M -187M -173M -328M -22.08B -333M -2.23B -876M -10.84B -868M -850M -37.56B
Logo ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
Employees
-
Date Price Change
09/07/26 9.536 -0.06%
08/07/26 €9.542 +0.23%
07/07/26 €9.520 -0.13%
06/07/26 €9.532 -4.78%
03/07/26 €10.01 -0.99%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
10.94USD
Average target price
20.29USD
Spread / Average Target
+85.43%

Quarterly revenue - Rate of surprise